Pandorum Technologies: The Indian Deep-Tech Company Bioengineering Human Tissues

India’s biotechnology sector is moving beyond conventional pharmaceuticals and diagnostics into one of the most demanding areas of modern medicine—rebuilding damaged human tissue.

Bengaluru-based Pandorum Technologies is developing regenerative products and laboratory tissue models by combining stem-cell biology, biomaterials, therapeutic exosomes, self-assembling cell systems and three-dimensional biofabrication. Its principal programmes include bioengineered corneal products intended to support eye regeneration and three-dimensional liver tissues designed for drug testing, disease modelling and possible future regenerative applications.

Pandorum’s work does not yet amount to manufacturing complete human organs ready for routine transplantation. Instead, the company is constructing functional tissue-like structures and regenerative environments that reproduce selected biological, structural and mechanical characteristics of native human tissue.

This distinction is important. A transplantable liver or complete eye is vastly more complex than a laboratory organoid, tissue patch or bioengineered corneal implant. Nevertheless, the ability to reproduce even part of a human organ’s architecture and biological behaviour can transform drug development, disease research and tissue-repair therapies.

From an Indian Academic Idea to a Regenerative-Medicine Company

Pandorum Technologies was incorporated in 2011 after its founders began exploring the possibility of combining engineering with cellular biology. The company was incubated at the Centre for Cellular and Molecular Platforms, or C-CAMP, in Bengaluru and received support under the Biotechnology Ignition Grant programme of the Biotechnology Industry Research Assistance Council in 2012.

It subsequently received support through BIRAC’s Small Business Innovation Research Initiative and raised private investment for the development of its tissue-engineering platforms. The company now operates research facilities in Bengaluru and maintains research and collaboration links in the United States.

Pandorum was co-founded by Tuhin Bhowmick, who serves as chief executive officer, and Arun Chandru, the company’s chief technology officer. Bhowmick’s background includes biophysics, biomaterials, protein engineering and computational biology, while Chandru trained in aerospace and systems engineering at the Indian Institute of Science.

The combination reflects the interdisciplinary nature of tissue engineering. Building biological tissue requires knowledge of cells and molecular signals, but it also involves structural design, material strength, fluid transport, manufacturing precision and systems integration.

What Tissue Engineering Means

Human tissues are not simply collections of cells. Cells survive and perform their specialised functions within a complex environment containing proteins, sugars, fibres, signalling molecules, blood vessels and mechanical support.

This surrounding network is known as the extracellular matrix. It provides the physical structure within which cells attach, communicate, multiply and organise themselves.

When tissue is severely injured, the original extracellular environment may be damaged or replaced by scar tissue. Supplying cells alone may therefore be insufficient. The cells also require a suitable scaffold, chemical signals and physical conditions that encourage them to behave like healthy tissue.

Pandorum’s approach attempts to recreate these conditions through a combination of:

• Tissue-mimicking biomaterials
• Stem-cell cultivation and cellular engineering
• Exosome-based regenerative signals
• Three-dimensional biofabrication and self-assembly

These technologies are being developed as a common platform that can be adapted to the cornea, liver, lungs and potentially other tissues.

Bio-Inks That Resemble Human Tissue

One of Pandorum’s core capabilities is the development of bio-instructive biomaterials.

A conventional medical material may simply fill a space, hold tissue together or prevent leakage. A bio-instructive material is designed to interact with cells and influence how they behave.

Pandorum has developed a proprietary cornea-specific bio-ink intended to reproduce important properties of the natural corneal extracellular matrix. The company says the material has been engineered for transparency and tissue-like mechanical and chemical behaviour.

Its characteristics can be adjusted to control adhesion, degradation and interaction with surrounding cells. This allows the material to provide temporary support while the patient’s own tissue grows or reorganises around it.

The material must remain transparent because the cornea acts as the eye’s front optical window. A structurally strong implant that blocks or distorts light would have limited value for restoring vision.

The biomaterial must also withstand blinking, tear flow, internal eye pressure and movements of the ocular surface while avoiding excessive inflammation or scarring.

Cellular Engineering and Stem-Cell Farming

Pandorum’s cellular-engineering platform focuses on expanding mesenchymal stem cells and other specialised cells under controlled two-dimensional and three-dimensional culture conditions.

Growing cells reliably at a laboratory or manufacturing scale is more difficult than maintaining a small academic cell culture. Researchers must preserve cell identity, biological activity and product consistency across large batches.

Pandorum describes its scalable culture process as cell farming. The system uses methods such as microcarriers and spheroid culture to increase the number of cells and optimise the biological substances they produce.

In spheroid culture, cells assemble into small three-dimensional clusters rather than spreading across a flat laboratory surface. This arrangement can reproduce aspects of natural cell-to-cell communication more effectively than conventional two-dimensional culture.

These engineered cell cultures can serve two purposes. Cells may be incorporated directly into tissue constructs, or they may be used as biological factories that produce regenerative molecules and extracellular vesicles.

Exosomes as Signals for Regeneration

An important part of Pandorum’s platform is based on exosomes.

Exosomes are nanoscale membrane-bound particles released by cells. They contain proteins, lipids and genetic material such as messenger RNA and microRNA, allowing cells to exchange biological instructions.

Pandorum cultivates stem cells under conditions intended to encourage the production of exosomes with anti-inflammatory, anti-fibrotic and tissue-repair properties. The company then isolates and characterises these particles for incorporation into regenerative formulations.

The objective is to obtain some of the regenerative signalling benefits associated with stem cells without necessarily placing large numbers of living cells directly into every therapeutic product.

A cell-free treatment could potentially offer advantages in manufacturing, storage, dosing and safety. However, exosome therapies remain an emerging field and require rigorous evidence regarding composition, potency, biodistribution, immune effects and long-term safety before widespread clinical use.

Building Tissue Through Biofabrication

Pandorum combines its cells, biological signals and biomaterials through three-dimensional biofabrication.

Bioprinting deposits bio-inks in controlled patterns to construct tissue-like structures. The printer must place cells and materials without exposing them to forces, heat or chemicals that destroy their viability.

Pandorum also uses self-assembly, in which cells organise themselves after being placed within an appropriate environment. The company describes its broader method as a form of four-dimensional bioprinting because the structure can continue changing and maturing over time after fabrication.

This time-dependent development is essential. A printed construct does not become functional tissue merely because it resembles an organ’s shape. The cells must communicate, reorganise, produce extracellular matrix and develop tissue-specific biological functions.

Bioengineered Cornea Programme

Pandorum’s most advanced therapeutic work is focused on the cornea—the transparent outer tissue at the front of the eye.

Corneal injury can result from infection, trauma, chemical burns, genetic disorders and severe inflammation. Damage may cause clouding, ulceration, thinning and scarring, preventing light from entering the eye normally.

Corneal transplantation remains an important treatment for advanced damage, but suitable donor tissue is limited. Donated corneas also vary in quality, and some patients face a high risk of transplant rejection.

Pandorum is developing a family of bioengineered corneal products that combine tissue-mimicking biomaterials with regenerative exosomes. The aim is to encourage the eye to repair damaged epithelium, stroma and associated nerves while reducing inflammation and fibrosis.

Kuragel: A Regenerative Corneal Scaffold

One of the company’s research programmes produced Kuragel, a biodegradable corneal hydrogel made using functionalised gelatin and hyaluronic acid.

The formulation can be cross-linked using light, allowing a liquid or gel-like material to form a stable scaffold at the treatment site. It was engineered to provide transparency, mechanical behaviour and adhesion resembling important characteristics of a healthy human cornea.

A peer-reviewed study published in iScience in 2024 reported results from a rabbit model involving injuries to the corneal epithelium and stroma. The researchers observed re-epithelialisation within one month and regeneration of stromal tissue and the sub-basal nerve plexus within three months.

These were preclinical animal findings rather than proof of effectiveness in human patients, but they provided scientific support for further development of the biomaterial as a regenerative corneal scaffold.

Kuragenx and the “Liquid Cornea” Concept

Pandorum’s flagship corneal programme is described by the company as Kuragenx, sometimes referred to as the “liquid cornea.”

The formulation combines a transparent biopolymeric solution with regenerative exosomes. After application, the material is intended to solidify using visible-light cross-linking and form a temporary matrix over or within the damaged corneal region.

The scaffold would gradually release biological signals while supporting the patient’s own cells as they migrate, multiply and rebuild the damaged tissue.

Pandorum is targeting difficult conditions involving corneal ulceration, inflammation, fibrosis, nerve damage and stromal thinning. The company has reported extensive preclinical evaluation and has established collaborations intended to support clinical translation.

Pandorum’s public information describes Northwestern University as a partner in preparations for a first-in-human study of Kuragenx. However, publicly available sources reviewed for this article do not establish that a completed human clinical trial has demonstrated the product’s safety or effectiveness.

Kuragenx should therefore be understood as an investigational regenerative therapy rather than an approved replacement for corneal transplantation.

Bioprinted Corneal Lenticules

The company is also developing bioengineered corneal lenticules.

A lenticule is a thin, disc-shaped structure designed to replace or reinforce part of the corneal stroma, which accounts for most of the cornea’s thickness.

Pandorum’s lenticules use cornea-mimicking biopolymers and proprietary bio-inks. Depending on the intended application, they may also incorporate cells or regenerative exosomes.

The objective is to create standardised tissue substitutes that can be manufactured with greater consistency than donated biological tissue and implanted without extensive suturing.

In 2024, Pandorum researchers published a peer-reviewed study on biopolymeric corneal lenticules produced through digital-light-processing bioprinting. The work examined whether the fabricated structures could reproduce relevant physical and biological characteristics required for a corneal substitute.

The technology could eventually support treatments for corneal thinning, stromal damage and other conditions in which only part of the cornea requires replacement or reinforcement.

Three-Dimensional Human Liver Tissues

Pandorum’s second major platform is focused on the liver.

The liver performs hundreds of biological functions, including metabolism, detoxification, protein production, nutrient storage and chemical processing. Because many drugs are metabolised in the liver, liver toxicity is a major cause of failure during pharmaceutical development.

Conventional laboratory testing often uses liver cells grown in flat culture plates. These cells can lose important characteristics after removal from their natural three-dimensional environment, limiting their ability to predict how a drug will behave inside the human body.

Pandorum produces three-dimensional hepatocyte spheroids intended to maintain liver-related functions such as albumin secretion and cytochrome P450 enzyme activity over longer culture periods. These models can be used to study drug metabolism, pharmacokinetics, toxicity and interactions between medicines.

Liver Organoids for Disease Modelling

A spheroid contains cells arranged in a three-dimensional cluster. A more complex organoid includes multiple cell types organised in a way that reproduces selected functions of an organ.

Pandorum’s liver organoids combine hepatocytes with cells such as Kupffer cells, hepatic stellate cells and liver endothelial cells.

Each performs a different role. Hepatocytes carry out many metabolic functions. Kupffer cells participate in immune responses. Stellate cells are involved in fibrosis, while endothelial cells form part of the liver’s vascular environment.

By combining these cell types, researchers can reproduce aspects of diseases involving fat accumulation, inflammation and scarring. Pandorum is developing organoid models for studying metabolic dysfunction-associated steatohepatitis and evaluating possible anti-steatotic, anti-inflammatory and anti-fibrotic drugs.

Such models could provide more human-relevant information than some traditional cell cultures and complement animal testing during early drug discovery.

They could also help pharmaceutical companies identify toxic or ineffective compounds before expensive clinical trials begin.

Towards Vascularised Mini-Livers

Pandorum’s longer-term liver programme involves the development of vascularised organoids, tissue patches and bio-artificial liver constructs.

A major obstacle to building larger tissue is the supply of oxygen and nutrients. Cells located close to the surface of a small organoid can obtain these substances from the surrounding culture medium. Cells inside a larger structure may die unless the tissue contains a network resembling blood vessels.

Creating a functional vascular system is therefore one of the central challenges of organ engineering.

Pandorum states that it is developing prototypes of three-dimensionally fabricated mini-organs or organ patches capable of connecting with host tissue after transplantation. This remains a developmental objective rather than an available transplant therapy.

The immediate practical value of the liver platform lies primarily in drug discovery, toxicity testing and disease modelling rather than replacing an entire failing human liver.

Laboratory Models Could Improve Drug Development

Drug development is expensive partly because laboratory and animal models do not always predict human responses accurately.

A compound may appear safe in a conventional cell culture but cause liver injury in clinical trials. Conversely, a potentially useful medicine may be abandoned because a simplified model fails to reproduce the relevant human biology.

Bioengineered human tissues could help researchers evaluate drug absorption, metabolism, toxicity and disease response in a more realistic environment.

They may also allow repeated testing using tissues created from cells carrying particular genetic traits or disease characteristics.

In the longer term, personalised tissue models could help researchers examine how individuals or patient groups respond differently to the same medicine.

These systems will not automatically eliminate animal studies or clinical trials. They could instead provide an additional layer of evidence and help researchers select better drug candidates before advancing to later stages.

Corneal Therapy and Liver Models Serve Different Purposes

Pandorum’s corneal and liver programmes should not be presented as though they have reached the same developmental stage or serve identical purposes.

The corneal programme is primarily therapeutic. Its hydrogels, lenticules and exosome-based formulations are intended to repair or replace damaged tissue in patients, subject to successful clinical testing and regulatory approval.

The liver programme is currently more strongly positioned as an in-vitro platform for pharmaceutical research, toxicology and disease modelling. Implantable liver patches and vascularised mini-organs represent longer-term research goals.

This difference reflects the complexity of the tissues involved. The cornea is thin, avascular and comparatively accessible to surgeons. The liver is a large, highly vascularised organ containing multiple specialised cell populations and a complex internal architecture.

Cell-Free Regenerative Therapies

Pandorum is also expanding beyond physical tissue constructs into cell-free regenerative medicine.

Instead of transplanting cells, a cell-free therapy delivers molecules or extracellular vesicles produced by cells. The aim is to activate the patient’s existing repair mechanisms without requiring the implanted cells to survive permanently.

Pandorum’s exosome platform is being investigated for corneal, liver and lung-related applications. The company is developing methods for controlling cell-culture conditions, enriching therapeutic cargo, purifying vesicles and measuring biological activity.

The scientific potential is considerable, but the field also faces major regulatory and manufacturing challenges. Exosome preparations can vary depending on the source cells, culture conditions, purification process and storage method.

A successful product must demonstrate consistent composition and biological potency from one manufacturing batch to another.

From Prototype to Medical Product

Creating a promising tissue in a research laboratory is only the first stage of developing a medical product.

Pandorum must demonstrate that its materials and biological components can be manufactured repeatedly under tightly controlled conditions. Regulators will require evidence covering sterility, toxicity, immune response, degradation, distribution, dosage and long-term safety.

Therapeutic products containing cells or exosomes can be more difficult to standardise than conventional chemical medicines. Living systems change in response to small variations in temperature, nutrients, handling and storage.

Bioengineered implants must also remain mechanically stable during surgery and healing. A corneal product must preserve transparency and optical quality while integrating with surrounding tissue.

Human clinical trials will ultimately determine whether encouraging laboratory and animal findings translate into meaningful improvements for patients.

Pandorum Filling the Strategic Gap of Make in India

Pandorum Technologies represents a strategically important category of Indian deep technology.

India has traditionally been recognised for producing generic medicines, vaccines and pharmaceutical services. Tissue engineering requires a different set of capabilities extending into biomaterials, cell manufacturing, organoid biology, bioprinting, nanotherapy and regenerative medicine.

Pandorum has built its central research and development operations in Bengaluru while using Indian biotechnology incubators and government-supported innovation programmes to move from an academic concept towards translational product development.

Its work contributes to domestic capability in:

• Human stem-cell culture
• Therapeutic exosome production
• Tissue-specific biomaterials
• Medical-grade bio-inks
• Three-dimensional bioprinting
• Corneal regeneration
• Human liver organoids
• Drug-toxicity testing
• Regenerative product manufacturing

These capabilities could support a wider ecosystem of hospitals, pharmaceutical companies, research institutes, medical-device manufacturers and biotechnology startups.

Reducing Dependence on Donor Tissue

The long-term promise of Pandorum’s corneal programme lies in reducing dependence on donated human tissue.

A bioengineered product could be manufactured in controlled batches, stored under defined conditions and supplied to hospitals according to demand.

It could also be designed for a specific type of injury rather than requiring replacement of the entire cornea.

Such technology would not immediately eliminate the need for conventional transplantation. Its success will depend on the severity and location of the disease, the patient’s condition and the clinical performance of the final product.

Nevertheless, even a therapy suitable for selected corneal injuries could help preserve donor corneas for patients who have no alternative.

A Platform Rather Than a Single Product

Pandorum’s significance lies in the fact that it is not developing only one medical implant.

Its underlying platform combines engineered cells, exosomes, biomimetic gels and fabrication methods that can be adjusted for different tissues.

The cornea demonstrates how a transparent scaffold and regenerative signals can be combined for an avascular tissue. The liver programme demonstrates how multiple cell populations can be assembled for metabolic testing and disease modelling. The lung programme explores the use of cell-derived vesicles for repairing inflammation and fibrosis.

Knowledge gained in one programme can strengthen the others. Improvements in cell farming can increase exosome production. Better biomaterials can improve both corneal implants and liver organoids. Advances in biofabrication can help researchers create more organised and reproducible tissues.

Scientific Promise with Necessary Caution

Terms such as “artificial organ,” “liquid cornea” and “mini-liver” can create the impression that complete replacement organs are already available.

Pandorum’s work is scientifically significant, but its technologies must be described according to their actual development stage.

The liver constructs are primarily research tissues and developmental organoid systems. They are not complete transplantable livers.

The corneal products have produced encouraging preclinical and peer-reviewed research findings, while clinical translation remains subject to formal trials and regulatory review.

Maintaining this distinction does not diminish the company’s achievement. Tissue engineering advances through progressive stages—from cells, to spheroids, to organoids, to tissue patches and eventually to clinically validated implants.

Pandorum is building Indian expertise across several of these stages.

Conclusion

Pandorum Technologies is bringing together biological science and precision engineering to develop a new generation of human-tissue technologies in India.

Its bioengineered corneal programme uses transparent biomaterials, bioprinting and regenerative exosomes to explore alternatives and complements to donated corneal tissue. Its liver platform creates three-dimensional human tissue models for testing drug metabolism, toxicity and complex diseases.

The company’s wider platform includes stem-cell farming, extracellular-vesicle engineering, bio-instructive materials, organoid development and multidimensional biofabrication.

Considerable work remains before these technologies can become routine medical treatments. Manufacturing consistency, clinical safety, regulatory approval, affordability and large-scale production must all be established.

Yet Pandorum’s work marks an important transition for Indian biotechnology—from manufacturing established biological products towards designing living tissues and regenerative systems from first principles.

In India’s expanding deep-tech ecosystem, Pandorum Technologies represents an ambitious attempt to manufacture not merely a device or medicine, but some of the biological building blocks needed to help the human body repair itself.

---

References

Pandorum Technologies
Official company overview, product pipeline, technology platform, leadership and research collaborations.

Pandorum Technologies
Official information on three-dimensional liver spheroids, multicellular organoids and developmental bio-artificial liver concepts.

iScience
“Kuragel: A Biomimetic Hydrogel Scaffold Designed to Promote Corneal Regeneration,” 2024.

Biomedical Materials
“Biopolymeric Corneal Lenticules by Digital Light Processing-Based Bioprinting: A Dynamic Substitute for Corneal Transplant,” 2024.

Biotechnology Industry Research Assistance Council
Official material on Pandorum’s functional human-tissue platforms and government-supported biotechnology development.

Centre for Cellular and Molecular Platforms
Official startup information on Pandorum’s bioengineered cornea and three-dimensional liver-tissue platform.

---